Biotech Values

[RockRat]

I agree with you, for the additional reason that wile he might be a good diagnostics CEO, he ran one of the stupidest late stage trials I've ever seen: of Flurbiprofen in AD. It was obvious even to me that it should have been scrapped in P2, but no, he went to P3 based on a subset analysis of a subset analysis.

The award should probably go to Celgene's CEO Sol Barer. No, he and his stock haven't done that much THIS year, but the last decade . . .

Regards, RockRat